Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine

MarketWatch · Jaimy Lee · 2026-11-06 12:15 UTC

The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

Moderna, best known for advancing mRNA technology, raised its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.

The biotech company announced Friday that it anticipates revenue growth of 15% and 25% this year. It had previously guided for 10% in revenue growth.

Read the full story at MarketWatch · All coverage of this story